We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.
- Authors
Sato, Hiromi; Narita, Shintaro; Tsuchiya, Norihiko; Koizumi, Atsushi; Nara, Taketoshi; Kanda, Sohei; Numakura, Kazuyuki; Tsuruta, Hiroshi; Maeno, Atsushi; Saito, Mitsuru; Inoue, Takamitsu; Satoh, Shigeru; Nomura, Kyoko; Habuchi, Tomonori
- Abstract
<bold>Background: </bold>Less evidence is known about the role of early changes in serum biomarker after androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Here we evaluated the impact of pre-treatment prognostic factors and early changes in serum biomarkers on prostate specific antigen (PSA) progression-free and overall survival rates in mHSPC.<bold>Methods: </bold>We retrospectively reviewed the medical records of 60 mHSPC patients (median age 72 years) treated with ADT whose laboratory data at baseline and following 12 weeks were available.<bold>Results: </bold>Forty-four patients (73%) had PSA progression and 27 patients (45.0%) died during a median follow-up of 34 months. The multivariable Cox hazard model demonstrated that a log-transformed baseline PSA level (p = 0.003) and an extent of bone disease (EOD) score of ≥3 (p = 0.004) were statistically associated with an increased risk for PSA progression whereas one unit increase in a log-transformed PSA change (baseline-12 weeks) was associated with a decreased risk for PSA progression (p = 0.004). For overall survival, a high level of alkaline phosphatase (ALP) at 12 weeks was associated with increased risk (p = 0.030) whereas a one-unit increase in the log-transformed PSA change was associated with decreased risk (p = 0.001).<bold>Conclusions: </bold>An increased level of PSA at baseline, or an EOD score of ≥3 may be a good predictor of PSA progression, and a high level of ALP at 12 weeks may be a risk predictor of death. A larger decline in PSA at 12 weeks from the baseline was associated with both PSA progression-free and overall survival time. Early changes in serum biomarkers may be useful in predicting poor outcomes in patients with mHSPC who are initially treated with ADT.
- Subjects
PROSTATE-specific antigen; PROSTATE cancer; ANDROGEN drugs; CANCER chemotherapy; METASTASIS
- Publication
BMC Urology, 2018, Vol 18, Issue 1, pN.PAG
- ISSN
1471-2490
- Publication type
journal article
- DOI
10.1186/s12894-018-0353-4